Bausch Health (BHC) insider sells 36,827 shares in plan trade

Rhea-AI Filing Summary

Bausch Health Companies Inc. (BHC) reported that Aimee J. Lenar, President, US Pharma, sold 36,827 Common Shares on August 19, 2026 at $7.03 per share in an open‑market transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2026, and Lenar now holds 334,853 Common Shares directly.

Insider Trade Summary 10b5-1

Net Seller: 36,827 shares

Net Sell 1 txn

Insider Lenar Aimee J.

Role President, US Pharma

Sold 36,827 shs ($259K)

Type	Security	Shares	Price	Value
Sale	Common Shares, No Par Value F1	36,827	$7.03	$259K

Holdings After Transaction: Common Shares, No Par Value — 334,853 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 21, 2026.

Key Figures

Shares sold: 36,827 Common Shares Sale price per share: $7.03 per share Shares held after transaction: 334,853 Common Shares +2 more

5 metrics

Shares sold 36,827 Common Shares Non-derivative sale on August 19, 2026

Sale price per share $7.03 per share Price for 36,827 Common Shares sold

Shares held after transaction 334,853 Common Shares Direct ownership following the August 19, 2026 sale

Rule 10b5-1 plan adoption date May 21, 2026 Plan under which the reported sale was executed

Number of sell transactions 1 Total reported non-derivative sales in this Form 4

Key Terms

Rule 10b5-1 plan, open market, Common Shares, No Par Value, Form 4

4 terms

Rule 10b5-1 plan regulatory

"sold in the open market pursuant to a Rule 10b5-l plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market market

"Represents shares of common stock sold in the open market"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

Common Shares, No Par Value financial

"security_title: "Common Shares, No Par Value""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did BHC disclose for Aimee J. Lenar?

Bausch Health Companies Inc. disclosed that Aimee J. Lenar sold 36,827 Common Shares on August 19, 2026 at a price of $7.03 per share in an open‑market sale, leaving her with 334,853 Common Shares held directly afterward.

Was the BHC insider sale by Aimee J. Lenar under a Rule 10b5-1 plan?

Yes. The filing states the 36,827 Common Shares were sold in the open market pursuant to a Rule 10b5-1 trading plan adopted by Aimee J. Lenar on May 21, 2026.

How many BHC shares does Aimee J. Lenar hold after the reported sale?

After the sale, Aimee J. Lenar directly holds 334,853 Common Shares of Bausch Health Companies Inc., according to the Form 4 disclosure.

What price did Aimee J. Lenar receive for the BHC shares sold?

Aimee J. Lenar sold 36,827 BHC Common Shares at a price of $7.03 per share in an open‑market or private transaction, as reported in the Form 4.

What is Aimee J. Lenar’s role at Bausch Health Companies Inc. (BHC)?

The reporting person, Aimee J. Lenar, is identified as President, US Pharma of Bausch Health Companies Inc. in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 04:34 PM Accepted by SEC EDGAR 08/20/2026 - 04:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lenar Aimee J.

(Last) (First) (Middle)

400 SOMERSET CORPORATE BLVD.

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bausch Health Companies Inc. [ BHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, US Pharma

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, No Par Value	08/19/2026		S		36,827(1)	D	$7.03	334,853	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock sold in the open market pursuant to a Rule 10b5-l plan adopted by the Reporting Person on May 21, 2026.

	/s/ Brianna M. Dorsi, attorney-in-fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)